|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Polo-like kinase 3 (PLK3) has been documented as a tumor suppressor in several types of malignancies.
|
31655629 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
<b>Conclusion:</b> Increased pre-treatment tumor levels of PLK3 and pT273 Caspase 8 correspond to improved disease-related outcomes among cervical cancer patients treated with CRT plus BT, representing a potential biomarker in this context.
|
31475104 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Polo-like kinase 3 (Plk3) is a serine/threonine protein kinase with a tumor suppressive function.
|
28857653 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Polo-like kinase 2 (Plk2) and Polo-like kinase 3 (Plk3) have been documented as a tumor suppressor and are lowly expressed in several types of cancer.
|
27423313 |
2016 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Clinicopathologically, PLK3 expression was associated with decreased tumour cell migration and lymph/blood vessel infiltration whereas higher levels of PLK1 were correlated with larger tumour sizes.
|
25818805 |
2015 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In this study, the expression of PLK1 and PLK3 was determined immunohistochemically in tissue specimen of normal ovaries (n=9), cystadenomas (n=17), borderline tumours (n=13) and ovarian carcinomas (n=77).
|
14970859 |
2004 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Furthermore, fluorescence in situ hybridization analyses show that the PRK gene localizes to chromosome band 8p21, a region that exhibits a high frequency of loss of heterozygosity in a variety of human cancers, including head and neck cancers, and that is proposed to contain two putative tumor suppressor genes.
|
10679924 |
2000 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Southern blotting analysis indicates that the prk gene is present in a single copy in the genome of tumors and normal cells.
|
8702627 |
1996 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Polo-like kinase 3 (PLK3) has been documented as a tumor suppressor in several types of malignancies.
|
31655629 |
2019 |
|
Keratoconus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ten-Year Outcomes of Progressive Keratoconus Management With the Athens Protocol (Topography-Guided Partial-Refraction PRK Combined With CXL).
|
31393985 |
2019 |
|
Keratoconus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Long-Term Stability With the Athens Protocol (Topography-Guided Partial PRK Combined With Cross-Linking) in Pediatric Patients With Keratoconus.
|
31169612 |
2019 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
TCGA data confirmed the association of low PLK3 expression with resistance to radiotherapy and BT (<i>p</i> < 0.05), as well as increased propensity for metastasis (<i>p</i> = 0.019).
|
31475104 |
2019 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
GSEA revealed that Plk3 was involved in proliferation and metastasis.
|
30863161 |
2019 |
|
Severe myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Charts of 256 consecutive eyes that underwent PRK with application of mitomycin-C 0.02% for high myopia were retrospectively reviewed.
|
30809386 |
2019 |
|
Keratoconus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Cross-linking can halt the disease progression, intrastromal corneal ring segments can improve the corneal shape and hence the visual quality and reduce the refractive error, PRK can correct mild-moderate refractive error, and intraocular lenses can correct from low to high refractive error associated with keratoconus.
|
29403662 |
2017 |
|
Severe myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Femtosecond laser-assisted LASIK versus PRK for high myopia: comparison of 18-month visual acuity and quality.
|
27699605 |
2017 |
|
Severe myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
To evaluate refractive outcomes of single-step transepithelial photorefractive keratectomy (TransPRK) versus alcohol-assisted PRK (EtOH-PRK) for the correction of high myopia.
|
27941045 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Polo-like kinase 2 (Plk2) and Polo-like kinase 3 (Plk3) have been documented as a tumor suppressor and are lowly expressed in several types of cancer.
|
27423313 |
2016 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Patients with high scores of Plk3 and pT273 caspase-8 showed increased local control (p = 0.011; p = 0.001), increased CSS (p = 0.011; p = 0.013) and OS (p = 0.024; p = 0.001), while the levels of pT273 caspase-8 were significantly associated (p = 0.033) with distant metastases.
|
27462786 |
2016 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
We also identified three biological pathways including glycolysis, cell cycle checkpoint II and plk3 pathways in which most genes are systematically up-regulated in many types of cancer.
|
17989776 |
2007 |
|
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
Kaplan-Meier analysis and Cox regression analysis were performed to evaluate the relationship between Plk3 and prognosis of patients with PCa.
|
30863161 |
2019 |
|
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Kaplan-Meier analysis and Cox regression analysis were performed to evaluate the relationship between Plk3 and prognosis of patients with PCa.
|
30863161 |
2019 |
|
Osteoporosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Using this MR approach we discovered that each additional year in AAM is associated with a modest reduction in FNK BMD (β = -0.072 se = 0.022, 95% CI (-0.115, -0.030), p = 0.001) and LS BMD ((β = -0.072, se = 0.025, 95% CI (-0.121, -0.023), p = 0.004), and therefore influences OP susceptibility.
|
30240960 |
2018 |
|
Osteoporosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We collected and analyzed summary statistics provided by large, multi-center GWAS studies of FNK (femoral neck) BMD (a major risk factor for osteoporosis) (n = 53,236) and RA (n = 80,799).
|
28854271 |
2017 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
We propose that suppression of Plk3 expression contributes to carcinogenesis and tumor progression induced by nickel compounds.
|
28515325 |
2017 |